Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Net Margin (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Net Margin for 6 consecutive years, with 784.7% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin changed N/A to 784.7% in Q4 2025 year-over-year; TTM through Dec 2025 was 1795.53%, a 157933.0% increase, with the full-year FY2025 number at 1795.53%, up 157933.0% from a year prior.
  • Net Margin was 784.7% for Q4 2025 at Relay Therapeutics, up from 10301.62% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 8349600.0% in Q4 2023 to a low of 82765.55% in Q2 2023.
  • A 5-year average of 504787.61% and a median of 11099.31% in 2021 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: plummeted -428647408bps in 2021, then skyrocketed 837627154bps in 2023.
  • Relay Therapeutics' Net Margin stood at 11897.0% in 2021, then crashed by -124bps to 26671.54% in 2022, then surged by 31405bps to 8349600.0% in 2023, then crashed by -100bps to 813.55% in 2024, then rose by 4bps to 784.7% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Net Margin are 784.7% (Q4 2025), 10301.62% (Q2 2025), and 1003.46% (Q1 2025).